LON:STXShield Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Shield Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 117 +8.00 (+7.34 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range 109.12Now: GBX 117▼ 118.6750-Day Range 82MA: GBX 94.92▼ 12752-Week Range 0.88Now: GBX 117▼ 195Volume94,691 shsAverage Volume48,665 shsMarket Capitalization£137.11 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions Chain Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingShield Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 200, Shield Therapeutics has a potential upside of 70.9% from its current price of GBX 117.Amount of Analyst CoverageShield Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesShield Therapeutics has received 209 “outperform” votes. (Add your “outperform” vote.)Underperform VotesShield Therapeutics has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentShield Therapeutics has received 59.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote “Outperform” if you believe STX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldShield Therapeutics does not currently pay a dividend.Dividend GrowthShield Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Shield Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Shield Therapeutics is -15.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shield Therapeutics is -15.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShield Therapeutics has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.30 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:STX Previous Symbol CUSIPN/A CIKN/A Webwww.shieldtherapeutics.com Phone+44-191-5118500Debt Debt-to-Equity Ratio0.06 Current Ratio1.53 Quick Ratio1.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£719,000.00 Price / Sales190.70 Cash FlowGBX 4.43 per share Price / Cash Flow26.43 Book ValueGBX 27.40 per share Price / Book4.27Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares117,189,000Market Cap£137.11 million Next Earnings DateN/A OptionableOptionable GBX 117 +8.00 (+7.34 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive STX News and Ratings via Email Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Shield Therapeutics (LON:STX) Frequently Asked Questions How has Shield Therapeutics' stock price been impacted by Coronavirus? Shield Therapeutics' stock was trading at GBX 121.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, STX shares have decreased by 3.7% and is now trading at GBX 117. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Shield Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Shield Therapeutics. What price target have analysts set for STX? 2 brokerages have issued 1-year price objectives for Shield Therapeutics' shares. Their forecasts range from GBX 200 to GBX 200. On average, they expect Shield Therapeutics' share price to reach GBX 200 in the next year. This suggests a possible upside of 70.9% from the stock's current price. View analysts' price targets for Shield Therapeutics. Has Shield Therapeutics been receiving favorable news coverage? News coverage about STX stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Shield Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Shield Therapeutics. Who are some of Shield Therapeutics' key competitors? Some companies that are related to Shield Therapeutics include HLS Therapeutics (HLS), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Next Science (NXS), Amryt Pharma (AMYT), Benchmark (BMK), ICC Labs (ICC), cbdMD (YCBD), Green Organic Dutchman (TGOD), ESSA Pharma (EPI), Probiotec (PBP), Althea Group (AGH), WeedMD (WMD) and Delta 9 Cannabis (NINE). View all competitors. What other stocks do shareholders of Shield Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and Skinbiotherapeutics (SBTX). Who are Shield Therapeutics' key executives? Shield Therapeutics' management team includes the following people: Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)Mr. Timothy William Watts, Chief Financial Officer (Age 61)Fleur Wood, Director of Investor RelationsMs. Lucy Bailey, Gen. Counsel & Company Sec.Ms. Suzanne Wood, Group HR Director What is Shield Therapeutics' stock symbol? Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX." How do I buy shares of Shield Therapeutics? Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Shield Therapeutics' stock price today? One share of STX stock can currently be purchased for approximately GBX 117. How big of a company is Shield Therapeutics? Shield Therapeutics has a market capitalization of £137.11 million and generates £719,000.00 in revenue each year. Shield Therapeutics employs 15 workers across the globe. What is Shield Therapeutics' official website? The official website for Shield Therapeutics is www.shieldtherapeutics.com. How can I contact Shield Therapeutics? Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500. This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
